51st Annual Meeting & ToxExpo - Society of Toxicology

San Francisco, California
The Thematic Track information can be found on pages 8–9.
sive, particularly for multigenerational reproductive and prenatal
developmental assessment. Furthermore, predicting adverse effects
of chemicals for reproductive and developmental outcomes has
been confounded by the lack of quantitative models that address the
complex molecular and physiological factors underlying reproductive
decrements and developmental malformations, and the life-stage and
generational sensitivities involved. There is currently a strong focus
on identifying endocrine-disrupting chemicals through a battery of
in vitro and in vivo screening tests. However, the shared complexities
and challenges of modeling reproductive, endocrine, and
developmental toxicity, and the parallel need for higher throughput
evaluation, creates the need for an integrated application of predictive
models for chemical prioritization and targeted testing. Ultimately,
predictive models of reproductive, endocrine, and developmental
toxicity will provide a critical component in the computational toxicology
toolbox that better informs regulatory testing decisions.
• Validation, Acceptance, and Extension of a Predictive Model
of Reproductive Toxicity Using Toxcast Data. Matthew Martin,
US EPA, Research Triangle Park, NC.
• Species-Specific Predictive Models of Developmental Toxicity
Using the ToxCast Chemical Library. Nisha Sipes, US EPA,
Research Triangle Park, NC.
• Test Strategies and Alternative Approaches for Developmental-
Reproductive Toxicity from the European Regulatory
Perspective. Aldert Piersma, National Institute for Public Health
and the Environment RIVM, Bilthoven, Netherlands.
• Building Bridges between High-Throughput Screening Data and
In Vivo Regulatory Guideline Tests: Application of Intermediate
Tier In Vitro Functional Assays in the Chemical Industry.
Edward Carney, The Dow Chemical Company, Midland, MI.
• Intelligent Approaches to DART Evaluations of Therapeutic
Proteins. Kary Thompson, Bristol-Myers Squibb Company,
New Brunswick, NJ.
Symposia
Characterizing Toxic Modes of Action
and Pathways to Toxicity
Cross-Species Analysis of Toxicogenomics
Data: Approaches for Assessing Differences in
Sensitivity and Conservation of Mode of Action
Tuesday, March 13, 9:00 AM to 11:45 AM
Chairperson(s): Russell S. Thomas, The Hamner Institutes for Health
Sciences, Research Triangle Park, NC, and J. Craig Rowlands, The
Dow Chemical Company, Midland, MI.
Sponsor:
Molecular Biology Specialty Section
Endorsed by:
Comparative and Veterinary Specialty Section
Mechanisms Specialty Section
Two fundamental, but interrelated, challenges in toxicology are to
identify a mode of action for a particular chemical and determine
whether a particular response will be conserved across species.
The determination of whether a response will be conserved usually
involves a mechanistic understanding of the molecular events and an
assessment of whether the processes and components that comprise
those events are present in both the model species and the species of
interest. In light of the relationship between gene expression changes
and the biological effects, cross-species toxicogenomic studies may
be used to identify potential modes of action for a chemical and
determine appropriate cross-species adjustment factors for use in a
risk assessment. We will evaluate the application of cross-species toxicogenomics
analysis of chemical toxicant-induced modes of action
across species for use in risk assessment in a series of highly focused
presentations. These issues will be of broad interest to investigators
and regulators across environmental, industrial, consumer products,
and pharmaceutical toxicology who perform and interpret crossspecies
studies to understand human health risks.
• Cross-Species Comparisons of Transcriptomic Alterations in
Human and Rat Primary Hepatocytes Exposed to Dioxin-Like
Chemicals. J. Craig Rowlands, The Dow Chemical Company,
Midland, MI.
• Application of Cross-Species Toxicogenomics to Understand
Rodent/Canine Mode-of-Action Differences in Drug-Induced
Toxicities. Timothy Ryan, Eli Lilly and Company, Indianapolis, IN.
• Cross-Species Transcriptomic Analysis of the Mouse and Rat
Lung Exposed to Chloroprene. Russell S. Thomas, The Hamner
Institutes for Health Sciences, Research Triangle Park, NC.
• Comparative Evaluation of Genomic Changes in the Human and
Mouse Bladder following Exposures to Inorganic Arsenic and
Methylated Metabolites. Harvey Clewell, The Hamner Institutes for
Health Sciences, Research Triangle Park, NC.
Scientific
up-to-date information at www.toxicology.org 75
Thematic Session